Saving Modern Medicine
700,000 people die annually from drug resistant infections. Our scientists are ready, the lab is booked and protocols are written. All we need to further our research is your help fill our test tubes with superbugs, antibiotics and other drugs, so that we can get on with saving modern medicine.
January 2018 - June 2018
Charity information: Antibiotic Research UK
Drug resistant infections are the biggest threat to modern medicine, with superbugs killing more than 700,000 people globally each year. In the UK alone, this annual figure is reported to be at least 12,000. Without a solution, by 2050 it is estimated that 10 million people could die worldwide each year from drug resistant infections. With the likelihood of new antibiotics far away in the future there is a clear need to find immediate ways to save current antibiotics.
Antibiotic Research UK (ANTRUK) is developing new antibiotic therapies, focusing on Antibiotic Resistance Breakers (ARBs). These are existing drugs which when combined with current antibiotics overcome the bacteria’s or ‘superbug’s’ resistance. Our initial research has found a number of drugs that can break antibiotic resistance in the most challenging types of bacteria. We now need your support to maintain this momentum into the next phase of our research.
Based on preliminary results, carry out further research into Antibiotic Resistance Breakers.
Activities» Test the 100 most promising antibiotic / ARB combinations at a range of concentrations with 4 of the most dangerous superbugs.
» Test double and triple antibiotic combinations at Warwick University with 4 of the most dangerous superbugs.
Identify combinations of antibiotics/drugs at optimum concentrations which are effective against 4 dangerous superbugs. Research can now be progressed to clinical trials.
The project will provide an interim solution to the global problem of drug resistant infections. By effectively re-positioning existing antibiotics and using them in combination with antibiotic resistance breakers, we hope to have effective therapies in clinic in 7-8 yrs, saving thousands of lives, while completely new antibiotics are developed (15-20 yrs). Success will ultimately be demonstrated by the number of people with drug resistant infections who respond positively to this new therapy.
There is a risk that the universities and pharmaceutical companies we work with don’t complete the research to time or to standard. To mitigate this we have carefully chosen our research partners (eg. University of Warwick, Cambridge University, Medicines Discovery Catapult) to ensure that they are of the highest quality. Their activity will be guided by our expert Science Committee, conducted under contract and regularly monitored by Prof Colin Garner, Prof Chris Dowson and Dr Lloyd Czaplewski.
Donors will be invited to join our mailing list where they will receive a monthly e-newsletter highlighting the project’s progress. They will also be able to follow developments by checking our social media channels which are regularly updated.
Budget - Project Cost: £67,673Loading graph....
Amount Heading Description £32,475 Scientists Specialist research scientists £7,000 Bacteria A range of clinical isolates of drug resistant bacteria £9,300 Drugs Antibiotics & potential antibiotic resistance breakers £1,700 Consumables Laboratory consumables £6,500 Lab costs Use of specialist lab equipment £10,698 Support costs Associated administration and support costs
Current Funding / Pledges
Source Amount Various charitable trusts and individual donors £43,673 Guaranteed
Antibiotic resistant infections are a growing global problem with an estimated 700,000 people dying each year. While ANTRUK is UK based, the application of our research is worldwide. Within this are some defined groups who are especially susceptible to drug resistant infections, such as the elderly, people living in deprived communities and those admitted to hospital for routine treatments which rely on effective antibiotics, such as hip replacements, cancer treatment and caesarean sections.
Antibiotic resistance is life-threatening, with the young and old being most at risk. If we don’t act now, treating infections caused by a cut or graze and medical procedures such as caesareans will become impossible. Without antibiotics life expectancy could reduce by up to 20 years. Therefore, anyone who contracts a drug resistant infection such as pneumonia, septicaemia, urinary tract infections and wound infections could benefit from our research. These are people whose lives we could save.
We’re the only charity dedicated to tackling antibiotic resistance, concentrating our efforts where they will yield the greatest benefit.
Our Science Committee are drawn from eminent scientists and clinicians – leaders in the field of drug resistant infections.
We work with some of the best university laboratories and pharmaceutical organisations.
As a ‘virtual’ organisation, our research takes place in other organisations’ laboratories, making us very cost effective.
Read more about the Charity running this project.
Professor Colin Garner
ANTRUK Chief Exec. University academic & scientific entrepreneur, heading up a cancer research laboratory at the University of York for almost 20 yrs
Dr Lloyd Czaplewski
Science Committee & Project Manager. 20+ yrs R&D experience. For last 15 yrs focused on antibacterial R&D (eg. bacterial cell wall biosynthesis)
Dr Chris Dowson
Trustee & Chair of Science Committee. Expert in evolution of bacterial antibiotic resistance. Chair at Warwick Uni Member of Medical Research Council
Dr David Wareham
Member of Science Committee. Clinical Snr Lecturer/Hon Consultant in Microbiology, Centre for Immunology & Infectious Disease, Blizard Inst & Barts
Could pay for a research scientist for a day
The idea of being plunged back into a world where the simplest infection could prove deadly because the drugs don’t work is terrifying.